New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 16, 2014
09:25 EDTACT, ACT, ACT, VRX, VRX, VRX, SGEN, SGEN, SGEN, REGN, REGN, REGN, MNK, MNK, MNK, INCY, INCY, INCY, GILD, GILD, GILD, CELG, CELG, CELG, BIIB, BIIB, BIIB, XLRN, XLRN, XLRNPiper Jaffray tech and biopharma analysts hold analyst/industry conference call
Technical Analyst Johnson, along with BioPharma Analysts, discuss the recent downturn in the biotech and specialty pharmaceuticals industries on an Analyst/Industry conference call to be held on April 17 at 10 am.
News For ACT;BIIB;CELG;GILD;INCY;MNK;REGN;SGEN;VRX;XLRN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
January 13, 2015
13:38 EDTACTActavis sees Q4 adjusted EPS beating consensus by 10%-15%
Subscribe for More Information
13:09 EDTBIIBBiogen CEO says company has strengthened R&D, to stay active in M&A
Subscribe for More Information
12:49 EDTVRXValeant CEO says 'unlikely' to work with Bill Ackman again
Subscribe for More Information
12:48 EDTCELGOn The Fly: Midday Wrap
Subscribe for More Information
12:48 EDTVRXValeant CEO says will have a 'number of clean quarters in a row'
Valeant CEO Michael Pearson said on CNBC that his company will have a "number of clean quarters in a row" in an effort to dispute attacks on its business model.
12:40 EDTREGNAmgen off highs after Express Scripts CEO talks PCSK9 costs
Subscribe for More Information
12:15 EDTGILDExpress Scripts CEO says Gilead relationship 'important' going forward
Express Scripts (ESRX) CEO George Paz at the J.P. Morgan Healthcare Conference said his company's relationship with Gilead (GILD) is "important" going forward. Paz said his company's goal is not to exclude drugs. He continues to discuss Express Scripts's deal with AbbVie (ABBV) and the company's goal of saving clients money with regards to healthcare costs.
12:10 EDTGILDExpress Scripts CEO says 'never stopped talking to Gilead'
Subscribe for More Information
11:43 EDTGILDGilead says negotiations ongoing with major U.S. payors for Harvoni
Subscribe for More Information
11:10 EDTGILDGilead drops, levels to watch
Subscribe for More Information
10:56 EDTVRXValeant sees continuation of Q3 trends in Q4
Subscribe for More Information
10:46 EDTVRXValeant doesn't see need to 'push a large deal for sake of doing large deal'
Sees double digit organic growth in 2014, 2015 and beyond. Says business development a priority for cash flow. Sees pursuing small and medium sized deals. Says doesn't see a need to "push a large deal for the sake of doing a large deal." Comments made at the JP Morgan Healthcare Conference. Valeant shares are up 2.1% to $158.76 in morning trading.
10:39 EDTVRXValeant repeats FY15 EPS view $10.10-$10.40, revenue $9.2B-$9.3B
Subscribe for More Information
10:38 EDTVRXValeant repeats Q4 cash EPS view $2.55+ vs. previous view $2.45-$2.55
Repeats Q4 revenue view $2.1B-$2.3B. Sees Q4 adjusted cash flow from operations about $600M. Says absorbed additional negative Fx impact of ~$40M to revenue, ~10c to cash EPS. Says FDA submission for Vesneo on track for Q2. Sees submission for sub-micron loteprednol gel 0.38% in late Q3, early Q4, and expects to launch product in 3Q16. Sees filing NDA for Arestin LCM in 2H15. Sees >12% same store organic growth for total company in Q4, >10% for FY. Sees Bausch + Lomb organic growth >10% for FY. Sees continued strong performance from Jublia, other recent product launches. Strategic initiates for 2015 include 10%-12% organic growth, cash conversion rate of >90%, achieve $500M+ revenues for key launch programs, including Jublia, Ultra, Luzu, Retin-A Micro 0.08%, Onexton. Comments from slides being presented at the JP Morgan Healthcare Conference.
09:36 EDTGILD, CELGActive equity options trading
Active equity options trading according to Track Data: AAPL AMD AA TWTR GILD C CELG TSLA GOOG
08:05 EDTACTActavis launches US generic specialty injectable portfolio
Actavis announced the launch of a portfolio of generic specialty injectable medications to be marketed to hospitals across the United States. Actavis will immediately begin marketing approximately 20 injectable products across a number of therapeutic categories in the U.S. The company hopes to be a leader in Oncology, with nearly a dozen marketed products including generic versions of Gemzar, Taxotere, Campostar and Zometa. Actavis also has an industry leading specialty injectable pipeline, with approximately 20 new filings under review at the U.S. Food and Drug Administration, as well as more than 50 additional projects currently in development.
07:43 EDTCELGCelgene price target raised to $142 from $109 at Bernstein
Subscribe for More Information
07:42 EDTVRX, GILDJPMorgan to hold a conference
33rd Annual Healthcare Conference is being held in San Francisco on January 12-15 with webcasted company presentations to begin on January 13 at 10:30 am; not all company presentations may be webcasted. Webcast Link
07:39 EDTVRXAmerican Academy of Cosmetic Surgery to hold a meeting
Subscribe for More Information
07:24 EDTCELGCelgene 2015 guidance conservative, says Cantor
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use